DYN · Insider Trading

Dyne Therapeutics, Inc. Common Stock

Full DYN quote
Iron condor setupsExpected moveIV rank historyFibonacci levelsInsider trading

Every open-market purchase and sale reported by DYN officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.

Form 4 Filings
50
most recent
Open-Market Buys
7
code P
Sales
33
code S
Reporting Insiders
11
current holders
DYN — Recent Form 4 Transactions (latest 2026-09-08)
FiledInsiderRole TypeSharesValue
2026-09-08 Johanna Friedl-Naderer Chief Commercial Officer Sell −1,085 −$25.41K
2026-09-08 John Cox CEO & President Sell −5,658 −$106.82K
2026-09-08 Douglas Kerr Chief Medical Officer Sell −5,035 −$115.55K
2026-08-17 Johanna Friedl-Naderer Chief Commercial Officer Sell −226 −$5.94K
2026-08-17 Douglas Kerr Chief Medical Officer Sell −1,556 −$40.89K
2026-08-17 Erick Lucera Chief Financial Officer Sell −1,797 −$47.23K
2026-08-17 Jason P Rhodes Director Sell −2,586,928 −$65.18M
2026-08-17 John Cox CEO & President Sell −4,986 −$131.03K
2026-07-29 Dirk Kersten Director Sell −261,460 −$6.67M
2026-07-08 Jason P Rhodes Director Sell −777,451 −$17.86M
2026-06-26 Erick Lucera Chief Financial Officer Sell −2,362 −$48.11K
2026-06-26 Jason P Rhodes Director Sell −267,760 −$5.65M
2026-06-24 Dirk Kersten Director Sell −263,962 −$5.46M
2026-06-23 Barry E Greene Director A +57,463 deriv. —
2026-06-22 Dirk Kersten Director Sell −84,355 −$1.70M
2026-06-17 Douglas Kerr Chief Medical Officer Sell −887 −$16.26K
2026-06-17 Johanna Friedl-Naderer Chief Commercial Officer Sell −145 −$2.66K
2026-06-17 John Cox CEO & President Sell −2,683 −$49.18K
2026-06-09 Carlo Incerti Director A +35,152 deriv. —
2026-06-09 David Charles Lubner Director A +35,152 deriv. —
2026-06-09 Brian S Posner Director Buy +2,000 +$33.88K
2026-06-09 Catherine Stehman-Breen Director A +35,152 deriv. —
2026-06-09 Jason P Rhodes Director A +35,152 deriv. —
2026-06-09 Dirk Kersten Director A +35,152 deriv. —
2026-06-09 Edward Hurwitz Director A +35,152 deriv. —
2026-06-05 Brian S Posner Director Buy +2,500 +$43.70K
2026-05-28 Brian S Posner Director Buy +2,000 +$36.42K
2026-05-22 Brian S Posner Director Buy +2,500 +$42.80K
2026-05-14 Douglas Kerr Chief Medical Officer Sell −1,564 −$28.72K
2026-05-14 Erick Lucera Chief Financial Officer Sell −1,448 −$26.59K
2026-05-14 Johanna Friedl-Naderer Chief Commercial Officer Sell −228 −$4.19K
2026-05-14 John Cox CEO & President Sell −3,311 −$60.79K
2026-05-06 Jason P Rhodes Director Sell −106,723 −$1.94M
2026-04-28 David Charles Lubner Director G −53,625 —
2026-04-27 Jason P Rhodes Director Sell −384,549 −$7.10M
2026-04-23 Dirk Kersten Director Sell −10,952 −$219.17K
2026-04-22 Jason P Rhodes Director Sell −834,302 −$16.48M
2026-04-21 Dirk Kersten Director Sell −337,248 −$6.82M
2026-04-17 Dirk Kersten Director Sell −99,613 −$2.03M
2026-04-03 Erick Lucera Chief Financial Officer Sell −5,727 −$106.75K
2026-04-01 Brian S Posner Director Buy +2,000 +$34.16K
2026-03-13 Brian S Posner Director Buy +2,000 +$38.70K
2026-03-13 Dirk Kersten Director Sell −129,672 −$2.53M
2026-03-11 Dirk Kersten Director Sell −688,788 −$13.15M
2026-03-10 Brian S Posner Director Buy +3,000 +$45.18K
2026-03-06 Douglas Kerr Chief Medical Officer Sell −904 −$13.47K
2026-03-06 Johanna Friedl-Naderer Chief Commercial Officer Sell −148 −$2.21K
2026-03-06 John Cox CEO & President Sell −2,732 −$40.71K
2026-02-17 Erick Lucera Chief Financial Officer A +65,000 —
2026-02-17 Douglas Kerr Chief Medical Officer A +85,000 —
DYN — Current Insider Holders
InsiderRole Shares HeldValue
Dirk Kersten Director 3,586,796 $55.04M
Jason P Rhodes Director 1,045,735 $16.05M
John Cox CEO & President 375,507 $5.76M
Oxana Beskrovnaya Chief Scientific Officer 195,840 $3.01M
Douglas Kerr Chief Medical Officer 163,854 $2.51M
Johanna Friedl-Naderer Chief Commercial Officer 152,897 $2.35M
Richard William Scalzo SVP, Head of Finance & Admin. 122,330 $1.88M
Erick Lucera Chief Financial Officer 119,766 $1.84M
Catherine Stehman-Breen Director 115,713 $1.78M
Edward Hurwitz Director 91,081 $1.40M
Brian S Posner Director 24,500 $375.95K
DYN Insider Trading FAQ
Who are the insiders at DYN?
11 officers, directors and 10%+ beneficial owners currently report holdings in DYN via SEC Form 4.
Are DYN insiders buying or selling?
Across the 50 most recent Form 4 filings for DYN, 7 were open-market purchases (code P) and 33 were sales (code S). Sales frequently reflect scheduled 10b5-1 plans or tax withholding rather than a view on the stock.
How current is DYN insider data?
Form 4 must be filed within two business days of the transaction, so this is close to real time. The most recent DYN filing is dated 2026-09-08.
How to read Form 4 activity

Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.

Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.

Full filing history and per-insider positions are on the DYN quote page; the site-wide leaderboard is on the insider transactions hub.

More on DYN
DYN full quote Insider Transactions Hub (all symbols) DYN iron condor setups DYN expected move DYN IV rank history DYN Fibonacci levels

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.